- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941388
A Phase I Study of INT-1868 Tablets in Healthy Adult Participants (INT-1868-I101) (INT-1868-I101)
A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, and Food-effect Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-1868 in Healthy Adult Participants
A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INT-1868 Tablets in Healthy Adult Participants.
-
Primary Objectives:
1. To evaluate the safety and tolerability of INT-1868 tablets after single and multiple doses in healthy adult participants;
-
Secondary Objectives:
1. To evaluate the PK characteristics of INT-1868 tablets after single and multiple doses in healthy adult participants; 2. To evaluate the effect of food on the PK characteristics of INT-1868 tablets;
-
Other Objectives:
- To evaluate the PD characteristics of INT-1868 tablets after single and multiple doses in healthy adult participants;
- To evaluate the PK characteristics of INT-1868 tablet metabolites (if applicable) after single and multiple doses in healthy adult participants;
- To assess the effect of INT-1868 tablets on C-QTc;
- To preliminarily evaluate the metabolic characteristics of INT-1868 tablets in humans.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Iris Liu
- Phone Number: 86 10-82089858 86-18513231616
- Email: irisliu@innatustherapeutics.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- Beijing Municipality -No. 101, Luyuan East Road, Tongzhou District, Beijing, China
-
Contact:
- Ruihua Dong
- Phone Number: 86-13810461342
- Email: ruihua_dong_rw@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants fully understand the purpose, nature, methods, and potential adverse reactions of the trial, voluntarily participate and sign the written Informed Consent Form, and are able to comply with the Protocol requirements to complete the study;
- Healthy trial participants aged 18 to 45 years (inclusive), regardless of gender (the proportion of males and females in each group shall not be less than 1/3);
- Body Mass Index (BMI: weight [kg]/height [m2) between 18.5 and 26.0 kg/m2Within the range (including boundary values), participants body weight ≥45 kg for females and ≥50 kg for males;
- The investigator determines that the participants is in good general health (assessed by medical history, surgical history, physical examination, vital signs, laboratory tests, electrocardiogram, etc., with no evidence of active or chronic cyclic diseases);
- Female participants of childbearing potential must agree to use effective contraception throughout the study period and for at least 90 days after the last dose; all female participants must have no plan for pregnancy or egg donation from the start of the study until at least 90 days after the last dose;
- Males of reproductive potential must agree to practice abstinence or use effective contraception throughout the study period and for at least 90 days after the last dose; all male trial participants must have no plan to donate sperm throughout the study period and for at least 90 days after the last dose.
Exclusion Criteria:
-
As assessed by the Investigator, presence ofClinically significantHistory of diseases, including but not limited to those of the gastrointestinal system, cardiovascular system, musculoskeletal system, endocrine system, blood and lymphatic system, kidneys, liver, respiratory system, nervous system, immune system, reproductive system, and lipid metabolism disorders; or any clinically significant abnormal results in physical examination, vital signs, ECG, or laboratory tests during the screening period as determined by the Investigator;
-
History of hospitalization or major surgery within the 6 months prior to screening, planned surgery during the study period, or history of bariatric surgery;
-
History of gastrointestinal, hepatic, or renal diseases that may affect drug absorption or metabolism;
-
History of hypertrophic scarring (keloid constitution), or skin abnormalities unsuitable for skin sample collection, or history of allergy to anesthetics or antibiotics (limited to trial participants intended for enrollment in the MAD study);
-
Participants with abnormal swallowing function, unable to swallow oral formulations normally;
-
During the screening period, the presence of any of the following electrocardiogram (ECG) abnormalities:
- Any ECG parameters outside the normal range or abnormal findings considered clinically significant by the Investigator;
- Any electrocardiogram (ECG) abnormalities (e.g., difficulty in measuring QT interval, conduction abnormalities) that the Investigator considers may affect the interpretation of cardiac safety and/or interfere with the assessment of adverse events after dosing;
- QT interval corrected by the Fridericia formula (QTcF) ≥450 ms for males and ≥460 ms for females;
-
Resting heart rate <50 beats per minute (bpm) or >100 beats per minute (bpm) during the screening period;
-
Systolic blood pressure ≥140 mmHg or <90 mmHg, and/or diastolic blood pressure ≥90 mmHg or <50 mmHg during the screening period;
-
Renal function judged by the Investigator based on clinical laboratory results, with an estimated Glomerular Filtration Rate (eGFR) <90 mL/min/1.73 m² calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation, or signs of renal impairment;
-
Presence of active liver disease or unexplained abnormalities in liver function tests (LFTs) during the screening period, defined as: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), γ-Glutamyl Transferase (γ-GGT), Alkaline Phosphatase (ALP), or Total/Direct Bilirubin levels exceeding the Upper Limit of the Reference Range (ULRR); or participants diagnosed with Gilbert's syndrome (constitutional non-hemolytic jaundice) are not allowed to participate in the study;
-
Participants with positive results for any of the following tests: Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody, or Treponema pallidum antibody;
-
Trial participants with active tuberculosis, with positive tuberculosis screening results during the screening period (if applicable);
-
Patients with malignant tumors (including those cured after previous illness);
-
Participants who experience acute illness during the screening period;
-
Presence of clinically significant infections, known inflammatory diseases, or a history of clinically significant infections within 14 days before the first dose administration;
-
Known or suspected history of drug abuse within the 2 years prior to screening, or history of alcohol abuse within the 90 days prior to screening;
-
Daily smoking of more than 5 cigarettes within the 6 months prior to screening, and inability to stop smoking and using nicotine products throughout the trial period;
-
Positive results for alcohol testing or urine drug abuse screening during the screening period;
-
Alcohol consumption exceeding 14 units per week within the 6 months prior to screening (1 unit of alcohol ≈ 360 mL of beer, 45 mL of spirits with 40% alcohol content, or 150 mL of wine), or inability to abstain from alcohol during the trial;
-
Alcohol consumption within 72 hours prior to the first dose;
-
Participation in any clinical study of Investigational Medicinal Product, device, biologic, or other investigational formulation within 30 days prior to the first dose (or within 5 half-lives, whichever is longer, if applicable);
-
Use of any medication (including prescription drugs, over-the-counter drugs, traditional Chinese herbal medicines, etc., but excluding anesthetics and antibiotics permitted by the protocol for skin tissue sample collection in MAD study participants) or health supplements within 14 days prior to the first dose (or within 7 half-lives, whichever is longer);
-
Vaccination within 30 days prior to the first dose, or planned vaccination during the study period;
-
Consumption of food or beverages containing caffeine, xanthines, or grapefruit-related components (e.g., coffee, strong tea, chocolate, etc.) within 48 hours prior to the first dose;
-
Total blood loss or blood donation exceeding 400 mL, plasma donation, or transfusion of blood and blood components within 30 days prior to the first dose; donation of bone marrow or peripheral stem cells within 90 days prior to the first dose;
-
Poor venous access that fails to meet the requirements for Pharmacokinetics blood sample collection; history of intolerance to blood collection during previous phlebotomy or blood donation;
-
Known hypersensitivity to INT-1868 or any of its excipients, or a history of unexplained weight loss, food allergies, or intolerance to specific foods;
-
Females who are pregnant or lactating, or females of childbearing potential who have engaged in unprotected sexual intercourse within 14 days prior to the first dose, or females with a positive pregnancy test during the screening period;
-
Participants who are a member of the investigator, site personnel, sponsor staff, or their relatives;
-
Participants who are unwilling to comply with trial restrictions and related requirements (e.g., dietary contraindications, inability to adhere to the trial-specified diets, high-fat meals, etc.);
-
The investigator considers it inappropriate for the 29) participants to participate in this study due to scientific reasons, compliance reasons, subject safety, or any other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Single Ascending Dose from 2.5 mg to 300 mg
Single Ascending Dose |
Escalating doses of 2.5, 10, 30, 100, 200, 300 mg of INT-1868; Single dose administration; Oral administration Escalating doses of 10, 30, 100 mg, 200 mg of INT-1868; QD for 14 days; Oral administration 100 mg INT-1868; Dosing on Day 1 (first dose) and Day 11 (second dose);Oral administration |
|
Experimental: Multiple Ascending Dose: 10 mg to 200mg
QD for 14 days; |
Escalating doses of 2.5, 10, 30, 100, 200, 300 mg of INT-1868; Single dose administration; Oral administration Escalating doses of 10, 30, 100 mg, 200 mg of INT-1868; QD for 14 days; Oral administration 100 mg INT-1868; Dosing on Day 1 (first dose) and Day 11 (second dose);Oral administration |
|
Experimental: Food Effect: 100 mg
|
Escalating doses of 2.5, 10, 30, 100, 200, 300 mg of INT-1868; Single dose administration; Oral administration Escalating doses of 10, 30, 100 mg, 200 mg of INT-1868; QD for 14 days; Oral administration 100 mg INT-1868; Dosing on Day 1 (first dose) and Day 11 (second dose);Oral administration |
|
Placebo Comparator: Placebo
Placebo for SAD, MAD and Food Effect |
INT-1868 Placebo;PO |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events(AEs)
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
The incidence, severity and types of AES |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
Laboratory tests: Complete Blood Count
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
Including complete blood count, blood biochemistry, coagulation function, and urinalysis |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
Physical examination
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
Including general condition (skin and lymph nodes), head (eyes, ears, nose, and throat), neck (thyroid gland), chest (lungs and heart), abdomen, spine and extremities, and nervous system |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
Treatment-emergent potentially clinically significant abnormalities in vital signs:blood pressure (mmHg)
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
Blood pressure (mmHg) |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
Treatment-emergent potentially clinically significant abnormalities in vital signs:pulse rate (bpm)
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
Pulse rate (bpm) |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
Treatment-emergent potentially clinically significant abnormalities in vital signs: respiratory rate (brpm)
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
Respiratory rate (brpm) |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
Treatment-emergent potentially clinically significant abnormalities in vital signs: body temperature (℃)
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
Body temperature (℃) |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
The main parameters of the 12-lead electrocardiogram (ECG) examination: heart rate (bpm)
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
Heart rate (bpm) |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
The main parameters of the 12-lead electrocardiogram (ECG) examination: PR Interval (milliseconds)
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
PR Interval (milliseconds) |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
The main parameters of the 12-lead electrocardiogram (ECG) examination: QRS duration (milliseconds)
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
QRS duration (milliseconds) |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
The main parameters of the 12-lead electrocardiogram (ECG) examination: QT interval (milliseconds)
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
QT interval (milliseconds) |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
|
The main parameters of the 12-lead electrocardiogram (ECG) examination: QTc (milliseconds)
Time Frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
QTc (milliseconds) |
SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics parameter: Cmax of INT-1868
Time Frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
Maximum plasma concentration |
SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
|
Pharmacokinetics parameter: Tmax of INT-1868
Time Frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
Time to reach maximum plasma concentration |
SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
|
Pharmacokinetics parameter: AUC0-t of INT-1868
Time Frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
Area under the concentration-time curve from time 0 to the time of the last measurable concentration (t) |
SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
|
Pharmacokinetics parameter: AUC0-24 of INT-1868
Time Frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
Area under the plasma concentration-time curve of the investigational product from 0 to 24 hours |
SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
|
Pharmacokinetics parameter: AUC0-inf of INT-1868
Time Frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
Area under the plasma concentration-time curve of the investigational product from time 0 to infinity |
SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
|
Pharmacokinetics parameter: t1/2 of INT-1868
Time Frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
Terminal elimination half-life |
SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
|
Pharmacokinetics parameter: λz of INT-1868
Time Frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
Terminal elimination rate constant |
SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
|
Pharmacokinetics parameter: CL/F of INT-1868
Time Frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
Apparent clearance |
SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
|
Pharmacokinetics parameter: Vd/F of INT-1868
Time Frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
Apparent volume of distribution |
SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
|
Pharmacokinetics parameter: tlag of INT-1868
Time Frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
Lag time |
SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
|
|
Pharmacokinetics parameter: Cmin,ss of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
Minimum plasma concentration at steady state |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
|
Pharmacokinetics parameter: Cmax,ss of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
Maximum plasma concentration at steady state |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
|
Pharmacokinetics parameter: Css,avg of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
Average plasma concentration at steady state |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
|
Pharmacokinetics parameter: AUC0-t of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
Area under the plasma concentration-time curve of the investigational product during the dosing interval (t) |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
|
Pharmacokinetics parameter: Tmax of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
Time to reach maximum plasma concentration at steady state |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
|
Pharmacokinetics parameter: λz of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
Terminal elimination rate constant |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
|
Pharmacokinetics parameter: t1/2 of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours(29 blood sampling time points)
|
Terminal elimination half-life |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours(29 blood sampling time points)
|
|
Pharmacokinetics parameter: Rac(Cmax)of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
Accumulation ratio based on Cmax |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
|
Pharmacokinetics parameter: Rac(AUC)of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
Accumulation ratio based on AUC |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
|
Pharmacokinetics parameter: CLss/F of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
Apparent clearance at steady state |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
|
Pharmacokinetics parameter: Vz/F of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
Apparent volume of distribution at steady state |
MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
|
|
Urinary pharmacokinetic parameters, including Ae and CumAe0-t, Fe, and CumFe0-tand CLr
Time Frame: SAD: pre-dose (-12 to 0 hours) and post-dose 0-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 24-48 hours, and 48-72 hours.
|
Amount of drug excreted in urine (Ae), cumulative amount excreted in urine (CumAe0-t), urinary excretion fraction (Fe), cumulative excretion fraction (CumFe0-t) and renal clearance (CLr) |
SAD: pre-dose (-12 to 0 hours) and post-dose 0-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 24-48 hours, and 48-72 hours.
|
|
Fecal pharmacokinetic parameters, including Ae and CumAe0-t, Fe, and CumFe0-t
Time Frame: SAD: pre-dose (-24 to 0 hours) and post-dose 0-24 hours, 24-48 hours and 48-72 hours
|
Amount of drug excreted in feces (Ae), cumulative amount excreted in feces (CumAe0-t), fecal excretion fraction (Fe), and cumulative excretion fraction (CumFe0-t) |
SAD: pre-dose (-24 to 0 hours) and post-dose 0-24 hours, 24-48 hours and 48-72 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacodynamics parameter: STAT6 of INT-1868
Time Frame: SAD:pre-dose (within 1 hour) and post-dose from Day 1 to Day 14 MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 38
|
Signal transducer and activator of transcription 6 (STAT6) in peripheral blood |
SAD:pre-dose (within 1 hour) and post-dose from Day 1 to Day 14 MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 38
|
|
Pharmacodynamics parameter: TARC of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
|
Thymus and activation-regulated chemokine |
MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
|
|
Pharmacodynamics parameter: IgE of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
|
Immunoglobulin E |
MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
|
|
Pharmacodynamics parameter: Eotaxin-3 of INT-1868
Time Frame: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
|
MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
|
|
|
Pharmacodynamics parameter: STAT6 of INT-1868
Time Frame: MAD: From Day-1 to Day 28
|
STAT6 in skin tissue |
MAD: From Day-1 to Day 28
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INT-1868-I101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.